Quantcast
Last updated on April 21, 2014 at 12:45 EDT

Diabetes Treatments: World Drug Market 2013-2023

September 30, 2013

Reportbuyer.com just published a new market research report: Diabetes Treatments: World Drug Market 2013-2023.

London (PRWEB) September 30, 2013

Report Details

How to find trends, opportunities and revenue prospects in treating diabetes

Where's the diabetic treatments market heading? How are those products performing? Visiongain's updated report gives you forecasted revenues there to 2023 and also explains R&D trends, outlooks and commercial opportunities.

Our study lets you assess sales data and predictions for the world antidiabetic medicines market, therapeutic submarkets, products and national markets. Those analyses show you that pharmaceutical field's most promising and lucrative segments.

Established and emerging diabetes-treating drugs have potential. Read on to scan features of their industry, find what drives it, and see what its future market could be worth.

Forecasts and other analyses to help you understand the diabetes drugs market

Our report gives you revenue forecasts to 2023, historical data, growth rates and market shares. It lets you discover quantitative and qualitative analysis, business outlooks and developments (R&D). You also gain 64 tables, 69 charts and two research interviews.

Do you want to find sales potential? With our analysis you can stay ahead in knowledge, benefiting your research, analyses and decisions. There you assess trends, innovations and opportunities for treating diabetes. You see what's happening, discovering possibilities.

There's rising need worldwide for drugs to treat human diabetes. For those agents, our work helps you find business areas that can prosper most, reducing the risk of your missing out.

The following sections show how you benefit from the new study.

Discover sales predictions for the world market and submarkets

Along with revenue prediction for the overall world market for treating diabetes, that work shows individual forecasts to 2023 for seven submarkets:

•Human insulins and analogues

•Alpha-glucosidase inhibitors

•Biguanides

•DPP-4 inhibitors

•Meglitinides

•Sulphonylureas

•Thiazolidinediones (glitazones).

Our report helps you identify potential and find opportunities there.

See prospects for manufacturers of novel drugs, generics and biosimilars, including follow-on and next-generation products.

Also, our investigation discusses what stimulates and restrains business. In addition, it lets you see what products are likely to achieve the most success.

See revenue forecasts for 25 leading drugs

How will leading antidiabetic agents perform to 2023 at world level? Our study forecasts individual sales of 25 products, including these brands:

•Lantus

•NovoLog

•Humalog

•Levemir

•Glucobay

•Basen

•Januvia

•Prandin

•Actos.

There you discover how high sales can go, from 2013, finding drugs and years with highest predicted revenues and growth. Also you compare competitors. You see what's happening, then, understanding trends, competition, challenges and opportunities.

Our report also divides its overall world revenue forecast into main geographical markets.

What prospects for leading regions and countries?

In developed and developing countries – especially India and China – there remain many opportunities for developing, manufacturing and selling diabetes treatments. There you see outlooks for producers and sellers of antidiabetic medicines.

Our analyses show you individual revenue forecasts to 2023 for eleven national markets:

•US

•Japan

•Germany, France, UK, Italy and Spain (EU5)

•Brazil, Russia, India and China (BRIC).

There you discover progress and outlooks. That way you assess the industry's future – hear about developments and find their significance.

Our forecasting shows revenue growth will occur in established pharma markets and in developing countries. In particular, product launches from 2013 to 2023 will change prescribing of antidiabetics and the commercial landscape for those medicines. See how.

Research and development – assess innovation, trends and possibilities

What about R&D – the pipeline for new drugs treating diabetes? In our study you see developmental trends for antidiabetic agents:

•Human insulins and analogues

•DPP-4 inhibitors

•Glucagon-like peptide (GLP)-1 agonists

•Sodium glucose co-transporter (SGLT)-2 inhibitors.

Discover progress. You assess innovations, hearing about developments and finding their significance.

See, then, what the future holds. For large companies and specialty pharma firms there exist many opportunities. Our study explains, discussing many issues.

What affects the antidiabetics sector?

Our report discusses issues and events affecting that industry and market from 2013, including these developments:

•Rising disease incidence and prevalence, including trends for obesity

•Demand for therapies in developing countries, esp. China

•Insulin analogues and other biotechnological advances

•Biosimilar insulins – changing patterns in competition

•Combination therapies for diabetes

•New drug delivery methods for insulins.

The work also discusses these and other aspects of diabetes treatments:

•Improvements to healthcare in developing countries

•R&D progress – potential to improve therapy

•Product safety – e.g. cardiovascular risk – and regulatory affairs

•Disease awareness affecting levels of diagnosis

•Reimbursement for the medicines – issues for payers

•Competition from generic drugs – threats and opportunities

•Secondary uses for antidiabetic medicines.

That way, you explore technological, economic, social and political (STEP) questions, assessing outlooks for that area of business.

Also, you analyse the diabetes treatment industry's strengths, weaknesses, opportunities and threats (SWOT). See, then, what the future holds.

Leading companies and 2017 market value

What happens next? Our study predicts the world market for antidiabetic drugs will reach $55.3bn overall in 2017 – with strong growth – and expand further to 2023. See how high revenues can go.

The analyses also show you what products and organisations hold greatest potential. Our work explores companies, including these:

•Novo Nordisk

•Eli Lilly

•Sanofi

•Bayer

•Takeda

•Merck & Co.

•Novartis

•Pfizer.

From 2013, the antidiabetic drugs market holds great promise to benefit patients, payers and companies. There will arise many technological and commercial opportunities. Our work predicts and explains them, helping you stay ahead.

Ten ways Diabetes Treatments: World Drug Market 2013-2023 helps you

To sum up, then, our investigation gives you the following knowledge:

•Revenues to 2023 for the world market for antidiabetic drugs – discover that industry's overall sales prospects

•Revenues to 2023 for 7 world-level submarkets – investigate the potential of that industry's components, finding the most promising areas for investments and revenues

•Revenues to 2023 for 25 leading products – find sales outlooks for top brands, seeing how they can compete and succeed

•Forecasts to 2023 for US, Japan, Germany, France, UK, Spain, Italy, Brazil, Russia, India and China – see national sales potentials, finding the best regions for revenues and growth

•Review of R&D for treating diabetes – investigate progress in its research areas, finding technological and medical possibilities

•Discussions and data for leading companies – hear about participants' strategies, capabilities, results and outlooks

•Interviews with authorities in that field – discover debates and opinions to help you stay ahead

•Competition and opportunities – see what affects that industry, learning what shapes its future, esp. prospects for sustaining and developing business

•Analysis of what stimulates and restrains the industry and market – assess challenges and strengths, helping you compete and gain advantages

•Prospects for established competitors and firms seeking to enter the sector -explore needs, practices and outlooks for future success.

You gain information found nowhere else

That work gives independent analysis. There you receive business intelligence found only in our report, seeing where technological and financial prospects are most rewarding.

With our study you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses and decisions, also saving time and getting you recognition for technological and commercial insight.

Ordering now lets you discover predictions to 2023 for diabetes trends and revenues

Our report is for everyone needing analysis of the industry and market for treating diabetes and related metabolic disorders. There you find data, trends, opportunities and predictions. Please order that report now.

Visiongain is a trading partner with the US Federal Government

CCR Ref number: KD4R6

Table of Contents

1. Executive Summary

1.1 Diabetes Drug Treatments: World Market Review

1.2 Content of the Report Chapters

1.3 Research and Analysis Methods

1.4 Scope of the Report

2. Introduction to Diabetes and Antidiabetic Drugs

2.1 What is Diabetes?

2.1.1 How is Diabetes Classified?

2.2 Disease Symptoms

2.3 Leading Risk Factors for Diabetes

2.3.1 Type 1 Diabetes

2.3.2 Type 2 Diabetes

2.4 Diagnosing Diabetes: Identifying the Presence of Biological Markers

2.5 Incidence and Prevalence Patterns in Diabetes

2.6 The Economic Burden of Diabetes

2.7 Leading Classes of Diabetic Medications

2.7.1 Type 1 Medications

2.7.1.1 Insulin

2.7.1.2 Oral Medications

2.7.1.3 Surgical Options

2.7.2 Type 2 Medications

2.7.2.1 Alpha-glucosidase Inhibitors

2.7.2.2 Biguanides

2.7.2.3 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

2.7.2.4 Meglitinides

2.7.2.5 Sulphonylureas

2.7.2.6 Thiazolidinediones

2.7.2.7 Other (Injectable) Medications

3. The World Diabetes Drug Market, 2013-2023

3.1 The World Diabetes Drug Market, 2011

3.1.1 The Diabetes Treatment Market by Drug Class, 2011

3.2 Top Selling Diabetes Drugs, 2011

3.3 The Global Diabetes Drug Market: Revenue Forecast, 2012-2023

3.3.1 The Global Diabetes Drug Market: Industry Trends, 2013-2023

3.3.1.1 Insulins to Maintain Market Dominance

3.3.1.2 DPP-4 Inhibitors: Targeting Developing Countries

4. Human Insulins and Analogues Market, 2013-2023

4.1 Human Insulins and Analogues Market, 2011

4.2 Human Insulins and Analogues: Revenue Forecast, 2012-2023

4.2.1 Human Insulins and Analogues: Market Trends, 2013-2023

4.2.1.1 Novel Methods of Insulin Delivery in Pipeline

4.2.1.2 New Insulin Analogues to Enter the Market in 2013-2014

4.2.1.3 Biosimilar Insulins: A Revolutionary Treatment Option on the Horizon?

4.2.1.4 Targeting China Offers Vast Market Prospects for Players

4.3 Lantus (Insulin Glargine; Sanofi)

4.3.1 Lantus: Revenue Forecast, 2012-2023

4.4 NovoLog (Insulin Aspart; Novo Nordisk)

4.4.1 NovoLog: Revenue Forecast, 2012-2023

4.5 Humalog (Insulin lispro; Eli Lilly)

4.5.1 Humalog: Revenue Forecast, 2012-2023

4.6 Levemir (Insulin detemir; Novo Nordisk)

4.6.1 Levemir: Revenue Forecast, 2012-2023

4.7 Humulin (Insulin isophane; Eli Lilly)

4.7.1 Humulin: Revenue Forecast, 2012-2023

4.8 Apidra (Insulin glulisine; Sanofi)

4.8.1 Apidra: Revenue Forecast, 2012-2023

5. Alpha-glucosidase Inhibitors Market, 2013-2023

5.1 Alpha-glucosidase Inhibitors Market, 2011

5.2 Alpha-glucosidase Inhibitors: Revenue Forecast, 2012-2023

5.2.1 Alpha-glucosidase Inhibitors: Market Trends, 2013-2023

5.2.1.1 Concerns over Gastrointestinal Side Effects May Limit Market Acceptance

5.3 Glucobay (Acarbose; Bayer AG)

5.3.1 Glucobay: Revenue Forecast, 2012-2023

5.4 Basen (Voglibose; Takeda)

5.4.1 Basen: Revenue Forecast, 2012-2023

5.5 Miglitol (Glyset)

5.5.1 Miglitol: Revenue Forecast, 2012-2023

5.6 Precose (Acarbose; Bayer)

5.6.1 Precose: Revenue Forecast, 2012-2023

6. Biguanides Market, 2013-2023

6.1 Biguanides Market, 2011

6.2 Biguanides: Revenue Forecast, 2012-2023

6.2.1 Biguanides: Market Trends, 2013-2023

6.2.1.1 Strong Efficacy in Treating Severe Hypoglycaemic Attacks

6.3 Glucophage (Metformin; Merck & Co.)

6.3.1 Glucophage: Revenue Forecast, 2012-2023

6.4 Fortamet (Metformin hydrochloride; Shionogi & Company)

6.4.1 Fortamet: Revenue Forecast, 2012-2023

6.5 Glumetza (Metformin hydrochloride; Santarus Inc.)

6.5.1 Glumetza: Revenue Forecast, 2012-2023

6.6 Diabex (Metformin hydrochloride; Alphapharm)

6.6.1 Diabex: Revenue Forecast, 2012-2023

7. DPP-4 Inhibitors Market, 2013-2023

7.1 DPP-4 Inhibitors Market, 2011

7.2 DPP-4 Inhibitors: Revenue Forecast, 2012-2023

7.2.1 DPP-4 Inhibitors: Market Trends, 2013-2023

7.2.1.1 Displacing Metformins' Leading Position

7.2.1.2 Disparity Between Drugs May Restrict the Market

7.3 Januvia (Sitagliptin; Merck & Co.)

7.3.1 Januvia: Revenue Forecast, 2012-2023

7.4 Galvus (Vildagliptin; Novartis)

7.4.1 Galvus: Revenue Forecast, 2012-2023

7.5 Glactiv (Sitagliptin; Ono Pharmaceuticals & Banyu Pharmaceuticals)

7.5.1 Glactiv: Revenue Forecast, 2012-2023

8. Meglitinides Market, 2013-2023

8.1 Meglitinides Market, 2011

8.2 Meglitinides: Revenue Forecast, 2012-2023

8.2.1 Meglitinides: Market Trends, 2013-2023

8.2.1.1 Combination Therapy: The Future Direction for Meglitinides?

8.3 Prandin (Repaglinide; Novo Nordisk)

8.3.1 Prandin: Revenue Forecast, 2012-2023

8.4 Starlix (Nateglinide; Novartis)

8.4.1 Starlix: Revenue Forecast, 2012-2023

8.5 Glufast (Mitiglinide; Kissei Pharmaceuticals and Takeda)

8.5.1 Glufast: Revenue Forecast, 2012-2023

9. Sulphonylureas Market, 2013-2023

9.1 Sulphonylureas Market, 2011

9.2 Sulphonylureas: Revenue Forecast, 2012-2023

9.2.1 Sulphonylureas: Market Trends, 2013-2023

9.2.1.1 Cardiovascular Complications May Affect Sales

9.3 Diamicron (Gliclazide; Servier)

9.3.1 Diamicron: Revenue Forecast, 2012-2023

9.4 Amaryl (Glimepiride; Sanofi)

9.4.1 Amaryl: Revenue Forecast, 2012-2023

9.5 Glucotrol XL (Glipizide; Pfizer)

9.5.1 Glucotrol XL: Revenue Forecast, 2012-2023

10. Thiazolidinediones Market, 2013-2023

10.1 Thiazolidinediones Market, 2011

10.2 Thiazolidinediones: Revenue Forecast, 2012-2023

10.2.1 Thiazolidinediones: Market Trends, 2013-2023

10.2.1.1 Possible Drug Efficacy in Prediabetes?

10.2.1.2 Full Clinical Value Needs to be Addressed

10.3 Actos (Pioglitazone; Takeda)

10.3.1 Actos: Revenue Forecast, 2012-2023

10.4 Avandia (Rosiglitazone; GSK)

10.4.1 Avandia: Revenue Forecast, 2012-2023

11. Leading National Diabetes Drug Markets, 2013-2023

11.1 Leading National Markets for Antidiabetic Drugs, 2011

11.2 Leading National Markets: Revenue Forecasts, 2012-2023

11.3 The US is the Largest Market for Antidiabetic Drugs

11.4 The Japanese Market

11.4.1 Increased Governmental Investments Will Drive Market

11.4.2 Novel Treatment Options Entering the Drug Landscape

11.5 Leading EU Markets for Antidiabetic Drugs: Revenues, 2011

11.5.1 The EU5 Market: Revenue Forecasts, 2012-2023

11.5.1.1 Germany: Disease Prevention Measures Require Improvement

11.5.1.2 UK: Trend of Combination Therapy

11.5.1.3 The Market in France and Regulatory Reform

11.5.1.4 Patient Incentives in Italy to Drive Diabetes Market

11.5.1.5 Cost-containment Measures in Spain Discouraging Companies?

11.6 China: The World's Largest Diabetic Population

11.6.1 Increased Presence of Multinational Corporations

11.6.2 Multi-Billion Dollar Investment to Improve Healthcare

11.7 India: Merck & Co. Leading the Way

11.7.1 Focusing on India's Rural Population

11.8 Strong Antidiabetic Drug Pipeline in Russia

11.8.1 Heavy Burden on Russian Patients May Reduce Compliance

11.9 Brazil: Regional Differences in Healthcare Access

11.9.1 Initiatives to Improve Awareness Gather Pace

12. The Diabetes Drug Market: R&D Pipeline, 2013

12.1 Discovering New Treatments and Molecular Targets

12.2 Human Insulins and Analogues: Pipeline Developments

12.2.1 LY2605541 (Eli Lilly/Boehringer Ingelheim)

12.2.2 Tresiba (Novo Nordisk)

12.2.3 LY2963016 (Eli Lilly/Boehringer Ingelheim)

12.3 DPP-4 Inhibitors: Pipeline Developments

12.3.1 Nesina (Takeda/Furiex Pharmaceuticals)

12.3.2 Trelagliptin (Takeda/Furiex Pharmaceuticals)

12.3.3 MK-3102 (Merck & Co.)

12.4 Other Novel Drug Targets

12.4.1 Glucagon-like Peptide (GLP)-1 Agonists

12.4.1.1 Albiglutide (formerly Syncria; GSK)

12.4.1.2 Dulaglutide (LY2189265; Eli Lilly)

12.4.1.3 Lixisenatide (Lyxumia; Sanofi)

12.4.1.4 Semaglutide (NN9535; Novo Nordisk)

12.4.2 Sodium Glucose Co-Transporter (SGLT)-2 Inhibitors

12.4.2.1 Ipragliflozin (ASP1941; Astellas Pharma/Kotobuki)

12.4.2.2 Canagliflozin (Invokana; Johnson & Johnson)

12.4.2.3 Empagliflozin (BI10773; Eli Lilly/Boehringer Ingelheim)

12.4.2.4 Dapagliflozin (Forxiga; Bristol-Myers Squibb/AstraZeneca)

13. Diabetes Drug Market: Industry Trends, 2013-2023

13.1 SWOT Analysis of the Diabetes Drug Market, 2013-2023

13.2 Strengths

13.2.1 Promising R&D Pipelines

13.2.2 Secondary Indications

13.2.3 Market Competition

13.3 Weaknesses

13.3.1 Lack of Disease Awareness

13.3.2 Reimbursement Issues

13.3.3 Increased Risk of Cardiovascular Events

13.4 Opportunities

13.4.1 Rising Disease Prevalence

13.4.2 Increased Demand in Pharmerging Markets

13.4.3 Novel Insulin Delivery Methods

13.5 Threats

13.5.1 Type 1 Diabetes Vaccine

13.5.2 Competition from Generic Drugs

13.5.3 Greater Regulatory Scrutiny

13.6 STEP Analysis of the World Diabetes Drug Market, 2013-2023

13.6.1 Social Development

13.6.2 Technological Advances

13.6.3 Economic Pressures

13.6.4 Political Issues

14. Research Interviews

14.1 Interview with an Academic Involved in Diabetes R&D

14.1.1 The Insulin Drug Market

14.1.2 Novel Delivery Technologies

14.1.3 Future Developments and Market Prospects

14.2 Interview with James Anderson, Generex Biotech

14.2.1 The Current Diabetes Drug Market

14.2.2 Generex's Oral-lyn™ Product and Buccal Drug Delivery

15. Conclusions

15.1 The Diabetes Drugs Market – Recent Results

15.2 Outlook for the World Diabetes Drugs Market, 2013-2023

15.2.1 Insulins Will Continue to Dominate the Market

15.3 Regional Outlook for The Diabetes Drugs Market, 2013-2023

15.4 Future Opportunities for Diabetes Drug Manufacturers

List of Tables

Table 2.1 Types of Injectable Insulin, 2013

Table 2.2 Commonly Prescribed Type 2 Diabetic Medications, 2013

Table 2.3 Other Classes of Drugs Used in Type 2 Diabetes, 2013

Table 3.1 The Global Diabetes Treatment Market: Revenues ($m) and Market Shares (%) by Type of Medication, 2011

Table 3.2 The Global Diabetes Treatment Market: Revenues ($m) and Market Shares (%) by Drug Class, 2011

Table 3.3 Top-Selling Diabetes Drugs: Revenues ($m) and Market Shares (%), 2011

Table 3.4 Diabetes Treatments: Revenue Forecasts ($bn) by Drug Class, 2012-2023

Table 4.1 Human Insulins and Analogues: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2011

Table 4.2 Human Insulins and Analogues: Revenue Forecasts ($bn) for Leading Drugs, 2012-2023

Table 4.3 Lantus: Drug Revenue Forecast ($bn), 2012-2023

Table 4.4 NovoLog: Drug Revenue Forecast ($bn), 2012-2023

Table 4.5 Humalog: Drug Revenue Forecast ($bn), 2012-2023

Table 4.6 Levemir: Drug Revenue Forecast ($bn), 2012-2023

Table 4.7 Humulin: Drug Revenue Forecast ($bn), 2012-2023

Table 4.8 Apidra: Drug Revenue Forecast ($bn), 2012-2023

Table 5.1 Alpha-glucosidase Inhibitors: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2011

Table 5.2 Alpha-glucosidase Inhibitors: Revenue Forecasts ($bn) for Leading Drugs, 2012-2023

Table 5.3 Glucobay: Drug Revenue Forecast ($bn), 2012-2023

Table 5.4 Basen: Drug Revenue Forecast ($bn), 2012-2023

Table 5.5 Miglitol: Drug Revenue Forecast ($bn), 2012-2023

Table 5.6 Precose: Drug Revenue Forecast ($bn), 2012-2023

Table 6.1 Biguanides: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2011

Table 6.2 Biguanides: Revenue Forecasts ($bn) for Leading Drugs, 2012-2023

Table 6.3 Glucophage: Drug Revenue Forecast ($bn), 2012-2023

Table 6.4 Fortamet: Drug Revenue Forecast ($bn), 2012-2023

Table 6.5 Glumetza: Drug Revenue Forecast ($bn), 2012-2023

Table 6.6 Diabex: Drug Revenue Forecast ($bn), 2012-2023

Table 7.1 DPP-4 Inhibitors: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2011

Table 7.2 DPP-4 Inhibitors: Revenue Forecasts ($bn) for Leading Drugs, 2012-2023

Table 7.3 Januvia: Drug Revenue Forecast ($bn), 2012-2023

Table 7.4 Galvus: Drug Revenue Forecast ($bn), 2012-2023

Table 7.5 Glactiv: Revenue Forecast ($bn), 2012-2023

Table 8.1 Meglitinides: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2011

Table 8.2 Meglitinides: Revenue Forecasts ($bn) for Leading Drugs, 2012-2023

Table 8.3 Prandin: Drug Revenue Forecast ($bn), 2012-2023

Table 8.4 Starlix: Drug Revenue Forecast ($bn), 2012-2023

Table 8.5 Glufast: Drug Revenue Forecast ($bn), 2012-2023

Table 9.1 Sulphonylureas: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2011

Table 9.2 Sulphonylureas: Revenue Forecasts ($bn) for Leading Drugs, 2012-2023

Table 9.3 Diamicron: Drug Revenue Forecast ($bn), 2012-2023

Table 9.4 Amaryl: Drug Revenue Forecast ($bn), 2012-2023

Table 9.5 Glucotrol XL: Drug Revenue Forecast ($bn), 2012-2023

Table 10.1 Thiazolidinediones: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2011

Table 10.2 Thiazolidinediones: Revenue Forecasts ($bn) for Leading Drugs, 2012-2023

Table 10.3 Actos: Drug Revenue Forecast ($bn), 2012-2023

Table 10.4 Avandia: Drug Revenue Forecast ($bn), 2012-2023

Table 11.1 The Global Diabetes Drugs Market: Revenues ($bn) and Market Shares (%) by Region, 2011

Table 11.2 The Diabetes Drugs Market: Revenue Forecasts ($bn) by Region, 2012-2023

Table 11.3 The US Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023

Table 11.4 The Japanese Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023

Table 11.5 The EU5 Diabetes Drugs Market ($bn), EU5 Market Shares (%) and Global Market Shares (%) by Country, 2011

Table 11.6 The EU5 Diabetes Drugs Market: Revenue Forecasts ($bn) by Leading Country (EU5), 2012-2023

Table 11.7 The German Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023

Table 11.8 The UK Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023

Table 11.9 The French Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023

Table 11.10 The Italian Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023

Table 11.11 The Spanish Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023

Table 11.12 The Chinese Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023

Table 11.13 The Indian Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023

Table 11.14 The Russian Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023

Table 11.15 The Brazilian Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023

Table 13.1 SWOT Analysis of the World Diabetes Drugs Market, 2012-2023

Table 15.1 The Global Diabetes Drugs Market: Revenue Forecast ($bn), in 2014, 2017, 2020 and 2023

Table 15.2 The Global Diabetes Drugs Market: Revenue Forecasts ($bn) and Market Shares (%) in Leading Regional Markets, 2014, 2017, 2020 and 2023

List of Figures

Figure 3.1 The Global Diabetes Treatment Market: Market Shares (%) by Type of Medication, 2011

Figure 3.2 The Global Diabetes Drugs Market: Revenues ($m) by Drug Class, 2011

Figure 3.3 The Global Diabetes Drugs Market: Market Shares (%) by Drug Class, 2011

Figure 3.4 The Global Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023

Figure 4.1 Human Insulins and Analogues: Revenues ($bn) by Leading Drugs, 2011

Figure 4.2 Human Insulins and Analogues: Market Shares (%) by Leading Drugs, 2011

Figure 4.3 Human Insulins and Analogues: Revenue Forecast ($bn), 2012-2023

Figure 4.4 Lantus: Drug Revenue Forecast ($bn), 2012-2023

Figure 4.5 NovoLog: Drug Revenue Forecast ($bn), 2012-2023

Figure 4.6 Humalog: Drug Revenue Forecast ($bn), 2012-2023

Figure 4.7 Levemir: Drug Revenue Forecast ($bn), 2012-2023

Figure 4.8 Humulin: Drug Revenue Forecast ($bn), 2012-2023

Figure 4.9 Apidra: Drug Revenue Forecast ($bn), 2012-2023

Figure 5.1 Alpha-glucosidase Inhibitors: Revenues ($bn) by Leading Drugs, 2011

Figure 5.2 Alpha-glucosidase Inhibitors: Market Shares (%) by Leading Drugs, 2011

Figure 5.3 Alpha-glucosidase Inhibitors: Revenue Forecast ($bn), 2012-2023

Figure 5.4 Glucobay: Drug Revenue Forecast ($bn), 2012-2023

Figure 5.5 Basen: Drug Revenue Forecast ($bn), 2012-2023

Figure 5.6 Miglitol: Drug Revenue Forecast ($bn), 2012-2023

Figure 5.7 Precose: Drug Revenue Forecast ($bn), 2012-2023

Figure 6.1 Biguanides: Revenues ($bn) by Leading Drugs, 2011

Figure 6.2 Biguanides: Market Shares (%) by Leading Drugs, 2011

Figure 6.3 Biguanides: Revenue Forecast ($bn), 2012-2023

Figure 6.4 Glucophage: Drug Revenue Forecast ($bn), 2012-2023

Figure 6.5 Fortamet: Drug Revenue Forecast ($bn), 2012-2023

Figure 6.6 Glumetza: Drug Revenue Forecast ($bn), 2012-2023

Figure 6.7 Diabex: Drug Revenue Forecast ($bn), 2012-2023

Figure 7.1 DPP-4 Inhibitors: Revenues ($bn) by Leading Drugs, 2011

Figure 7.2 DPP-4 Inhibitors: Market Shares (%) by Leading Drugs, 2011

Figure 7.3 DPP-4 Inhibitors: Revenue Forecast ($bn), 2012-2023

Figure 7.4 Januvia: Drug Revenue Forecast ($bn), 2012-2023

Figure 7.5 Galvus: Drug Revenue Forecast ($bn), 2012-2023

Figure 7.6 Glactiv: Drug Revenue Forecast ($bn), 2012-2023

Figure 8.1 Meglitinides: Revenues ($bn) by Leading Drugs, 2011

Figure 8.2 Meglitinides: Market Shares (%) by Leading Drugs, 2011

Figure 8.3 Meglitinides: Revenue Forecast ($bn), 2012-2023

Figure 8.4 Prandin: Drug Revenue Forecast ($bn), 2012-2023

Figure 8.5 Starlix: Drug Revenue Forecast ($bn), 2012-2023

Figure 8.6 Glufast: Drug Revenue Forecast ($bn), 2012-2023

Figure 9.1 Sulphonylureas: Revenues ($bn) by Leading Drugs, 2011

Figure 9.2 Sulphonylureas: Market Shares (%) by Leading Drugs, 2011

Figure 9.3 Sulphonylureas: Revenue Forecast ($bn), 2012-2023

Figure 9.4 Diamicron: Drug Revenue Forecast ($bn), 2012-2023

Figure 9.5 Amaryl: Drug Revenue Forecast ($bn), 2012-2023

Figure 9.6 Glucotrol XL: Drug Revenue Forecast ($bn), 2012-2023

Figure 10.1 Thiazolidinediones: Revenues ($bn) by Leading Drugs, 2011

Figure 10.2 Thiazolidinediones: Market Shares (%) by Leading Drugs, 2011

Figure 10.3 Thiazolidinediones: Revenue Forecast ($bn), 2012-2023

Figure 10.4 Actos: Drug Revenue Forecast ($bn), 2012-2023

Figure 10.5 Avandia: Drug Revenue Forecast ($bn), 2012-2023

Figure 11.1 The Global Diabetes Drugs Market: Revenues ($bn) by Region, 2011

Figure 11.2 The Global Diabetes Drugs Market: Market Shares (%) by Region, 2011

Figure 11.3 The US Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023

Figure 11.4 The Japanese Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023

Figure 11.5 The EU5 Diabetes Drugs Market: Revenues ($bn) by Country, 2011

Figure 11.6 The EU5 Diabetes Drugs Market: Market Shares (%) by Country, 2011

Figure 11.7 The EU5 Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023

Figure 11.8 The German Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023

Figure 11.9 The UK Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023

Figure 11.10 The French Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023

Figure 11.11 The Italian Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023

Figure 11.12 The Spanish Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023

Figure 11.13 The Chinese Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023

Figure 11.14 The Indian Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023

Figure 11.15 The Russian Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023

Figure 11.16 The Brazilian Diabetes Drugs Market: Revenue Forecast ($bn), 2012-2023

Figure 15.1 The Global Diabetes Drugs Market: Revenue Forecast ($bn), in 2014, 2017, 2020 and 2023

Figure 15.2 Injectable and Non-Injectable Medications for Diabetes: Revenue Forecasts ($bn), 2012-2023

Figure 15.3 The Global Diabetes Drugs Market: Revenue Forecasts ($bn) in Leading Regional Markets, 2014, 2017, 2020 and 2023

Companies Listed

Ajinomoto

Alphapharm

American Diabetes Association

Associacao Nacional de Assistencia ao Diabetico (ANAD, Brazil)

Astellas

AstraZeneca

Banyu Pharmaceuticals

Bayer

Biocon

Boehringer Ingelheim

Bristol-Myers Squibb

Depomed

Diabetes UK

Diamyd Medical

Eisai

Eli Lilly

European Medicines Agency (EMA)

Food and Drug Administration (US FDA)

Furiex Pharmaceuticals

Genentech

Generex Biotechnology Corporation

GlaxoSmithKline (GSK)

Glenmark Pharmaceuticals

Human Genome Sciences

International Diabetes Federation (IDF)

Johnson & Johnson (J&J)

Kissei Pharmaceuticals

Kotobuki Pharma

Lupin

MannKind Corporation

Merck & Co.

Merck Serono

Ministry of Health (MoH, Germany)

Ministry of Health, Labour and Welfare (MHLW, Japan)

Mylan

National Institute of Health and Clinical Excellence (NICE, UK)

Novartis

Novo Nordisk

Ono Pharmaceuticals

Oramed Pharmaceuticals

Pfizer

Roche

Sanofi

Santarus

Servier

Shantha Biotechnics

Shionogi Pharmaceuticals

Shreya Life Sciences

Sun Pharma

Takeda

Transdermal Specialties

World Health Organization (WHO)

Zydus Cadila

Read the full report:

Diabetes Treatments: World Drug Market 2013-2023

http://www.reportbuyer.com/pharma_healthcare/therapeutic/diabetes_treatments_world_drug_market_2013_2023.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

For more information:

Sarah Smith

Research Advisor at Reportbuyer.com

Email: query@reportbuyer.com

Tel: +44 208 816 85 48

Website: http://www.reportbuyer.com

For the original version on PRWeb visit: http://www.prweb.com/releases/2013/9/prweb11177460.htm


Source: prweb